- Home
- NBIX vs CHRW Comparison
NBIX vs CHRW Comparison
Compare NBIX & CHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- CHRW
- Stock Information
- Founded
- NBIX 1992
- CHRW 1905
- Country
- NBIX United States
- CHRW United States
- Employees
- NBIX N/A
- CHRW N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- CHRW Oil Refining/Marketing
- Sector
- NBIX Health Care
- CHRW Consumer Discretionary
- Exchange
- NBIX Nasdaq
- CHRW Nasdaq
- Market Cap
- NBIX 12.2B
- CHRW 10.7B
- IPO Year
- NBIX 1996
- CHRW 1997
- Fundamental
- Price
- NBIX $126.55
- CHRW $92.63
- Analyst Decision
- NBIX Strong Buy
- CHRW Buy
- Analyst Count
- NBIX 20
- CHRW 19
- Target Price
- NBIX $163.20
- CHRW $113.00
- AVG Volume (30 Days)
- NBIX 971.0K
- CHRW 1.1M
- Earning Date
- NBIX 07-31-2025
- CHRW 07-30-2025
- Dividend Yield
- NBIX N/A
- CHRW 2.68%
- EPS Growth
- NBIX N/A
- CHRW 64.94
- EPS
- NBIX 2.96
- CHRW 4.19
- Revenue
- NBIX $2,412,600,000.00
- CHRW $17,359,385,000.00
- Revenue This Year
- NBIX $16.29
- CHRW N/A
- Revenue Next Year
- NBIX $15.08
- CHRW $4.77
- P/E Ratio
- NBIX $42.79
- CHRW $22.12
- Revenue Growth
- NBIX 21.73
- CHRW N/A
- 52 Week Low
- NBIX $84.23
- CHRW $84.24
- 52 Week High
- NBIX $157.98
- CHRW $114.82
- Technical
- Relative Strength Index (RSI)
- NBIX 64.01
- CHRW 39.58
- Support Level
- NBIX $122.66
- CHRW $93.08
- Resistance Level
- NBIX $126.00
- CHRW $94.50
- Average True Range (ATR)
- NBIX 2.55
- CHRW 1.57
- MACD
- NBIX -0.33
- CHRW -0.46
- Stochastic Oscillator
- NBIX 72.06
- CHRW 5.41
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 61% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (27%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.